Emma Andrus, Associate Editor

A case study explores a rare overlap of hidradenitis suppurativa and porokeratosis, highlighting unique histopathology and complications.

A study found that UK adults living with psoriasis and vitiligo were better able to self-manage the psychological implications of their condition.

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

Post treatment discontinuation, most centers conduct imaging every 3 months during the first year of remission.

The recommendations place an emphasis on the utility of ultrasound-guided placement to enhance safety.

DFD-29, FDA-approved in 2024, revolutionizes rosacea management by addressing both erythema and inflammatory lesions with a novel extended-release formulation.

UVF dermoscopy enhances scabies detection, especially in dark skin, with optimal results when combined with polarized light examination.

Palvella begins its phase 2 TOIVA trial of Qtorin rapamycin gel for cutaneous venous malformations, targeting the mTOR pathway.

A Finnish review highlights imprecise use of L23.8 and L23.9 codes for allergic contact dermatitis.

Share your insights and anticipation with us.

The FDA recently proposed a new rule requiring standardized asbestos testing in talc-containing cosmetics to protect consumers from potential harm.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of January.

Dermatology Times asked our readers to share what conferences they are looking forward to in 2025.

Click here to view Dermatology Times' comprehensive list of health awareness days, months, weeks, and initiatives for 2025.

Explore the standout moments and expert insights from Dermatology Times' Cutaneous Connection podcast episodes in 2024.

Discover the most impactful insights and expert advice from Dermatology Times' 2024 Interview Intersection column.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies and clinical research from the year.

Explore the top dermatology news of 2024, highlighting breakthroughs, innovations, and key clinical insights shaping the future of skin care and treatment.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in aesthetic/cosmetic dermatology this year.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in vitiligo this year.

Dermatology Times is looking back on the top dermatology news headlines from 2024.

Dermatology Times is looking back on the top stories in dermatology that involve strides in skin health equity: addressing disparities for skin of color, women, LGBTQ+ patients, and improving care access.

Messina, senior VP of Aesthetics R&D at Allergan Aesthetics, highlights key trends shaping the aesthetic medicine landscape in 2025.

Dermatology Times is looking back on the top stories in dermatology from the month of December.

Dermatology Times is recapping our top expert interviews from the month of December.

The "whole body" study at Northwestern will be lead by Amy Paller, MD, begins soon.

Itisha S. Jefferson, a patient advocate and medical student, discusses the significance of new ICD-10 codes for CCCA and FFA, improving diagnosis and care.

Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.

Jackson discusses EVO756, a promising MRGPRX2 antagonist targeting mast cells to treat chronic inflammatory diseases like spontaneous urticaria.

Karan Lal, DO; Lisa Swanson, MD; James Song, MD; Andrew Alexis, MD, MPH; and Lawrence Eichenfield, MD, discussed the complexities of vitiligo care and the potential of innovative topical therapies.